Genetic advances distract from rare disease work

Genetic advances should not distract the UK from improving the care of rare non-hereditary diseases, rheumatologists say.

Yesterday they set out their own proposals for diseases such as lupus, scleroderma and ANCA associated vasculitis.

They warn that patients may face delays in diagnosis and treatment of up to seven years – leading them at risk of permanent disability and death.

They called for a collaborative approach to the problem, including work to include knowledge of the conditions among all health professionals.

The rheumatologists call for national audits of rare conditions and improved data through disease registries.

And they call for regionally coordinated networks of care.

The rheumatologists say the current UK rare diseases strategy has centred on genomics and the 80% of rare diseases with a genetic origin.

Dr Peter Lanyon, president of the British Society of Rheumatology, said: “This report sets out a vision of how the stakeholders within our community can work together to improve the lives of people with rare rheumatic and musculoskeletal disorders. These have largely gone under the radar of policymakers and those who commission and deliver health services.

"We hope to redress that through the collaborative approach outlined in this report, to ultimately help deliver better care and outcomes.”

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index